Anti-FA12/ F12/ HAE3 monoclonal antibody

Anti-FA12/ F12/ HAE3 antibody for FACS & in-vivo assay

Target products collectionGo to F12/F12 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T38509-Ab-1/ GM-Tg-hg-T38509-Ab-2Anti-Human F12 monoclonal antibodyHuman
GM-Tg-rg-T38509-Ab-1/ GM-Tg-rg-T38509-Ab-2Anti-Rat F12 monoclonal antibodyRat
GM-Tg-mg-T38509-Ab-1/ GM-Tg-mg-T38509-Ab-2Anti-Mouse F12 monoclonal antibodyMouse
GM-Tg-cynog-T38509-Ab-1/ GM-Tg-cynog-T38509-Ab-2Anti-Cynomolgus/ Rhesus macaque F12 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T38509-Ab-1/ GM-Tg-felg-T38509-Ab-2Anti-Feline F12 monoclonal antibodyFeline
GM-Tg-cang-T38509-Ab-1/ GM-Tg-cang-T38509-Ab-2Anti-Canine F12 monoclonal antibodyCanine
GM-Tg-bovg-T38509-Ab-1/ GM-Tg-bovg-T38509-Ab-2Anti-Bovine F12 monoclonal antibodyBovine
GM-Tg-equg-T38509-Ab-1/ GM-Tg-equg-T38509-Ab-2Anti-Equine F12 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T38509-Ab-1/ GM-Tg-hg-T38509-Ab-2; GM-Tg-rg-T38509-Ab-1/ GM-Tg-rg-T38509-Ab-2;
GM-Tg-mg-T38509-Ab-1/ GM-Tg-mg-T38509-Ab-2; GM-Tg-cynog-T38509-Ab-1/ GM-Tg-cynog-T38509-Ab-2;
GM-Tg-felg-T38509-Ab-1/ GM-Tg-felg-T38509-Ab-2; GM-Tg-cang-T38509-Ab-1/ GM-Tg-cang-T38509-Ab-2;
GM-Tg-bovg-T38509-Ab-1/ GM-Tg-bovg-T38509-Ab-2; GM-Tg-equg-T38509-Ab-1/ GM-Tg-equg-T38509-Ab-2
Products NameAnti-F12 monoclonal antibody
Formatmab
Target NameF12
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-F12 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-ab-233Pre-Made Garadacimab biosimilar, Whole mAb, Anti-F12 Antibody: Anti-HAE3/HAEX/HAF therapeutic antibody
    Target AntigenProducts DevelopingMulti-species FA12/ F12/ HAE3 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-T38509
    Target NameF12
    Gene ID2161,58992,306761,699875,489090,100313488,280789,100068589
    Gene Symbol and SynonymsF12,FXII,HAE3,HAEX,HAF
    Uniprot AccessionP00748,D3ZTE0,P98140
    Uniprot Entry NameFA12_HUMAN,FA12_RAT,FA12_BOVIN
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, INN Index
    DiseaseN/A
    Gene EnsemblENSG00000131187
    Target ClassificationN/A

    The target: F12, gene name: F12, also named as HAE3, HAEX, HAF. This gene encodes coagulation factor XII which circulates in blood as a zymogen. This single chain zymogen is converted to a two-chain serine protease with an heavy chain (alpha-factor XIIa) and a light chain. The heavy chain contains two fibronectin-type domains, two epidermal growth factor (EGF)-like domains, a kringle domain and a proline-rich domain, whereas the light chain contains only a catalytic domain. On activation, further cleavages takes place in the heavy chain, resulting in the production of beta-factor XIIa light chain and the alpha-factor XIIa light chain becomes beta-factor XIIa heavy chain. Prekallikrein is cleaved by factor XII to form kallikrein, which then cleaves factor XII first to alpha-factor XIIa and then to beta-factor XIIa. The active factor XIIa participates in the initiation of blood coagulation, fibrinolysis, and the generation of bradykinin and angiotensin. It activates coagulation factors VII and XI. Defects in this gene do not cause any clinical symptoms and the sole effect is that whole-blood clotting time is prolonged. [provided by RefSeq, Jul 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.